Skip to Content

Ferriprox (deferiprone) Disease Interactions

There are 2 disease interactions with Ferriprox (deferiprone):


Deferiprone (Includes Ferriprox) ↔ Agranulocytosis/Neutropenia

Severe Potential Hazard, Moderate plausibility

Applies to: Neutropenia, Infection - Bacterial/Fungal/Protozoal/Viral

Fatal agranulocytosis and neutropenia can occur with the use of deferiprone. It is recommended to obtain an absolute neutrophil count before initiating treatment with deferiprone and monitor weekly thereafter or as clinically appropriate. Manage agranulocytosis/neutropenia prior to initiating treatment. Therapy should be interrupted if neutropenia develops or if an infection develops. Do not resume therapy in patients who have developed agranulocytosis and do not rechallenge patients who develop neutropenia unless potential benefits outweigh potential risks.


Deferiprone (Includes Ferriprox) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

A clinical study to evaluate the effect of impaired hepatic function on the pharmacokinetics of deferiprone showed that mild and moderate hepatic impairment do not influence the pharmacokinetics of deferiprone and major metabolite, deferiprone 3-O-glucuronide. Based on the results, no dose adjustment is required in patients with mildly or moderately hepatic impairment. Caution is recommended when using this agent in patients with severe hepatic impairment as the pharmacokinetics of deferiprone and deferiprone have not been evaluated. It is recommended to monitor serum transaminase values monthly during therapy and to consider interruption if there is a persistent increase in serum transaminase levels. Close monitoring is recommended.

Ferriprox (deferiprone) drug Interactions

There are 300 drug interactions with Ferriprox (deferiprone)

Ferriprox (deferiprone) alcohol/food Interactions

There is 1 alcohol/food interaction with Ferriprox (deferiprone)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.